Supplementary Figure S10 from Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trial

Authors: Christine Desmedt, Ha-Linh Nguyen, François Richard et al.
Publication:
Published: Unknown date
Source: Crossref
Back to Search View Original Cite This Article

Abstract

<jats:p>&lt;p&gt;Association of clinicopathological and treatment variables with DFS and DRFS in ER+/HER2- ILC patients with cH/gL risk.&lt;/p&gt;</jats:p>

Keywords

passociation clinicopathological treatment variables drfs

Related Articles

Supplementary Figure 9 from Targeting the NAD&lt;sup&gt;+&lt;/sup&gt; Salvage Pathway Blocks Metabolic Recovery and Enhances β-Lapachone Toxicity in NQO1-Expressing Glioblastoma Cells

Bruce Chang-Gu, Tuvshintugs Baljinnyam et al. - Unknown

Read More
Supplementary Figure S3 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade

Julian Blagg, Philippe Riou et al. - Unknown

Read More
Supplementary Table S2 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies

Marie-Anne Goyette, Christopher Graser et al. - Unknown

Read More
Supplementary Table S6 from &lt;i&gt;Helicobacter pylori&lt;/i&gt; Infection and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis

Longgang Zhao, Yun Chen et al. - Unknown

Read More
Data from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies

Marie-Anne Goyette, Christopher Graser et al. - Unknown

Read More
Journal Ideas PyMinds Charcha More
PORE

About

About Us

Resources

Help Centre Research Guides CiteScore

Legal

Terms of Service Privacy Policy Cookie Policy Accessibility

Connect

Contact Us
© 2026 PORE. Content available under CC BY-NC 4.0